A biotechnology platform leveraging engineered Agrobacterium rhizogenes strains to create composite plants with enhanced root systems for increased soil carbon sequestration. By developing auxotrophic bacterial mutants, this technology enables field deployment of composite plants that shift fixed carbon from shoots to roots, boosting carbon transfer to soil through root biomass and exudation.
This biotechnology platform addresses the critical challenge of soil carbon sequestration by engineering composite plants with enhanced root systems. The approach harnesses Agrobacterium rhizogenes, a bacterium that naturally induces "Crazy Root" disease, redirecting fixed carbon from shoot and fruit production to extensive root proliferation. By creating auxotrophic mutants of A. rhizogenes, the technology enables field deployment of composite plants that can transfer significantly more carbon to soil through root biomass and exudation of carbon compounds. This solution has potential applications in carbon farming, soil health improvement, and climate change mitigation across multiple crop systems.
Core technology:
Key features:
The technology is currently at TRL 3-4 (experimental proof of concept to laboratory validation). The research team has over two decades of experience working with A. rhizogenes and has consistently demonstrated root over-proliferation in multiple plant systems under controlled laboratory conditions. The next phase involves creating and testing single, double, and triple auxotrophic mutants for their ability to induce transgenic roots while maintaining containment. Initial field validation will occur under microplot conditions to monitor root proliferation, carbon fixation potential, and bacterial elimination over growing seasons. Additional assessments of microbial biomass and composition are planned if sufficient funding is secured.
The Ohio State University is a comprehensive public land‑grant research university in Columbus, serving one of the nation’s largest student populations and a broad research enterprise. Industry partners engage through an integrated academic medical center for clinical translation, a campus‑adjacent innovation district for co‑located projects, and a statewide extension network that pilots solutions across Ohio. Corporate engagement provides a single front door for sponsored research, talent pipelines, and streamlined agreements. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, USDA, DoD, and NASA. A dedicated technology transfer office and venture support help protect IP, license technologies, and launch startups.